Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40ZYR | ISIN: US04390B1052 | Ticker-Symbol: 36X0
Siehe auch ASCENTAGE PHARMA GROUP INTERNATIONAL
Stuttgart
27.06.25 | 08:07
32,800 Euro
-0,61 % -0,200
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Chart 1 Jahr
5-Tage-Chart
ASCENTAGE PHARMA GROUP INTERNATIONAL ADR 5-Tage-Chart

Aktuelle News zur ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer1
FrASCENTAGE-B (06855): FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME-
18.06.HSI Down 269 pts; HSTI Down 77 pts; MEITUAN Down over 3%; CHINAHONGQIAO, UNITEDENERGY GP, ASCENTAGE, OCUMENSION-B, SHANGHAI IND H Hit New Highs; Market Turnover Rises4
18.06.HSI Down 281 pts; HSTI Down 83 pts; MEITUAN Down over 3%; UNITEDENERGY GP, ASCENTAGE, FORTUNE REIT, GUANGDONG INV Hit New Highs4
ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln
16.06.ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST RESULTS FROM MULTIPLE CLINICAL STUDIES IN 2025 EUROPEAN HEMATOLOGY ASSOCIATION ...-
16.06.ASCENTAGE PHARMA GROUP INTERNATIONAL: EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL138ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers...
► Artikel lesen
11.06.CICC Lifts ASCENTAGE-B's TP to HKD69 on Impressive APG-2575 Data2
10.06.ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer-
10.06.ASCENTAGE PHARMA GROUP INTERNATIONAL: Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress1
03.06.ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer-
03.06.ASCENTAGE PHARMA GROUP INTERNATIONAL: Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors66ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers...
► Artikel lesen
03.06.ASCENTAGE PHARMA GROUP INTERNATIONAL: Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report1
23.05.ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 202555ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers...
► Artikel lesen
23.05.ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS RESULTS FROM TWO CLINICAL STUDIES AT 2025 ASCO ANNUAL MEETING, INCLUDING AN ORAL ...2
20.05.ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer-
19.05.ASCENTAGE-B (06855): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 19, 2025-
30.04.ASCENTAGE-B (06855): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING-
30.04.ASCENTAGE-B (06855): SECOND PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 19, 2025-
30.04.ASCENTAGE-B (06855): SUPPLEMENTAL CIRCULAR - (1) PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME; (2) PROPOSED AMENDMENTS TO THE 2022 RSU SCHEME; (3) PROPOSED ...-
29.04.AACR 2025: Quintet of investigational oncological drugs puts Ascentage on positive ascent-
Weiter >>
85 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1